Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2015 (2015), Article ID 518982, 2 pages
Case Report

Thrombus Formation in Left Atrium on Dabigatran Therapy

1St. Joseph’s Regional Medical Center, 703 Main Street, Paterson, NJ 07503, USA
2Ohio State University, Columbus, OH 43210, USA

Received 15 December 2014; Revised 11 February 2015; Accepted 12 February 2015

Academic Editor: Yoko Miyasaka

Copyright © 2015 Priyank Shah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Dabigatran is a direct thrombin inhibitor, approved in the United States for stroke prevention in nonvalvular atrial fibrillation and prevention and treatment of thromboembolism. It has been also used in patients with documented left atrial thrombus, where treatment with dabigatran effectively led to thrombus resolution. We present a rare case of left atrial thrombus formation in a patient with chronic atrial fibrillation being treated with dabigatran 150 mg twice a day. The patient presented with multiple embolic strokes. There are only three such cases reported in the literature till date, all of whom had thrombus in the left atrium. The possible mechanisms of dabigatran failure include compensatory increase in upstream coagulation factors due to single level downstream blockade of thrombin, lack of inhibition of all available thrombin, and lack of monitoring measures that can be implemented in common clinical laboratories that lead to failure to assess adherence, which in turn can lead to dabigatran failure.